|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0017262,
umls-concept:C0038952,
umls-concept:C0087111,
umls-concept:C0185117,
umls-concept:C0332281,
umls-concept:C0439590,
umls-concept:C0684249,
umls-concept:C0694888,
umls-concept:C1122962,
umls-concept:C1335212,
umls-concept:C1516213,
umls-concept:C2911684
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2007-4-5
|
|
pubmed:abstractText |
We and other researchers have previously reported that pulmonary adenocarcinomas with epidermal growth factor receptor (EGFR) mutations are usually sensitive to gefitinib, an EGFR-specific tyrosine kinase inhibitor, although this relationship is not complete. In this study, we searched for mutations or changes in the expression of genes downstream to EGFR and evaluated their relationship with the effectiveness of gefitinib.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/KRAS protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/PIK3CA protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/PTEN Phosphohydrolase,
http://linkedlifedata.com/resource/pubmed/chemical/PTEN protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Phosphatidylinositol 3-Kinases,
http://linkedlifedata.com/resource/pubmed/chemical/Protein Kinase Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Protein-Tyrosine Kinases,
http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Quinazolines,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, Epidermal Growth Factor,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Markers, Biological,
http://linkedlifedata.com/resource/pubmed/chemical/gefitinib,
http://linkedlifedata.com/resource/pubmed/chemical/ras Proteins
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1556-1380
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
1
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
629-34
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:17409929-Adult,
pubmed-meshheading:17409929-Aged,
pubmed-meshheading:17409929-Aged, 80 and over,
pubmed-meshheading:17409929-Antineoplastic Agents,
pubmed-meshheading:17409929-Female,
pubmed-meshheading:17409929-Gene Expression,
pubmed-meshheading:17409929-Humans,
pubmed-meshheading:17409929-Lung Neoplasms,
pubmed-meshheading:17409929-Male,
pubmed-meshheading:17409929-Middle Aged,
pubmed-meshheading:17409929-Mutation,
pubmed-meshheading:17409929-PTEN Phosphohydrolase,
pubmed-meshheading:17409929-Phosphatidylinositol 3-Kinases,
pubmed-meshheading:17409929-Protein Kinase Inhibitors,
pubmed-meshheading:17409929-Protein-Tyrosine Kinases,
pubmed-meshheading:17409929-Proto-Oncogene Proteins,
pubmed-meshheading:17409929-Quinazolines,
pubmed-meshheading:17409929-Receptor, Epidermal Growth Factor,
pubmed-meshheading:17409929-Survival Rate,
pubmed-meshheading:17409929-Tumor Markers, Biological,
pubmed-meshheading:17409929-ras Proteins
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients.
|
|
pubmed:affiliation |
Department of Thoracic Surgery, Aichi Cancer Center Central Hospital, Nagoya, Japan.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
